Shield Therapeutics (LON:STX) Stock Price Passes Below Fifty Day Moving Average – Time to Sell?

Shield Therapeutics plc (LON:STX)’s stock price crossed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of GBX 10.47 and traded as low as GBX 9.50. Shield Therapeutics shares last traded at GBX 10.17, with a volume of 542,858 shares changing hands.

Wall Street Analyst Weigh In

Separately, Peel Hunt reissued a “buy” rating and issued a GBX 15 price target on shares of Shield Therapeutics in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, Shield Therapeutics presently has an average rating of “Buy” and a consensus target price of GBX 15.

Shield Therapeutics Trading Up 1.7%

The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The firm has a market capitalization of £108.62 million, a price-to-earnings ratio of -5.09 and a beta of 1.42. The business has a fifty day moving average price of GBX 10.47 and a 200 day moving average price of GBX 8.82.

About Shield Therapeutics

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.